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ABSTRACT 
Obesity, defined as a body mass index of 30 or above, is the result of an imbalance of 
energy intake and energy expenditure. In the last decade, the obesity prevalence has 
truly reached epidemic proportions with major effects on public health. Obesity is 
closely associated with insulin resistance, type 2 diabetes, hyperlipidemia and 
atherosclerosis. On the other end of the spectra, cancer cachexia is a poor diagnostic 
factor in cancer patients. It is characterized by a state of unintentional weight loss, 
primarily of body fat but also of lean body mass. Although the mechanisms behind the 
loss of adipose tissue are not completely understood, lipolysis seems to be a major 
factor. 
 
Adipose tissue is an important metabolic and endocrine organ. One of the most 
important functions of the adipocyte is lipolysis, the hydrolysis of triglycerides to free 
fatty acids (FFA) and glycerol. This is a tightly regulated process of great importance to 
the whole-body metabolism. The FFAs can either be released into the circulation, to be 
used as energy substrate by other organs and tissues, or utilized within the adipocyte for 
re-esterification or lipid oxidation. The process of lipid oxidation in adipocytes is 
controlled in part by the pyruvate dehydrogenase complex (PDC), an important 
regulator of substrate oxidation in adipocytes. This complex is inactivated when 
phosphorylated by pyruvate dehydrogenase kinases (PDKs), which promotes lipid 
oxidation rather than glucose oxidation. 
 
The aim of this thesis was to investigate how two factors, the liver x receptor (LXR) 
and cell death-inducing DNA fragmentation factor-α-like effector A (CIDEA) affect 
adipose tissue metabolism. LXR is a nuclear receptor and a known regulator of 
cholesterol, lipid and carbohydrate metabolism. CIDEA is almost exclusively expressed 
in white adipocytes in humans and can affect critical metabolic functions such as 
lipolysis.  
 
In paper I, we investigated the role of CIDEA in cancer cachexia. We measured levels 
of CIDEA in subcutaneous adipose tissue from subjects suffering from cancer cachexia 
and compared these to weight-stable cancer patients and noncancer patients. Levels of 
CIDEA mRNA were increased in cancer cachexia and correlated with elevated levels 
of FFAs and weight loss. Over-expression of CIDEA increased fatty acid oxidation in 
human adipocytes in culture and decreased glucose oxidation. Furthermore, augmented 
levels of CIDEA enhanced the expression of PDK1 and PDK4, and the 
phosphorylation of PDC. In accordance with this, mRNA levels of PDK1 and PDK4 in 
the clinical material correlated with CIDEA expression. In conclusion, CIDEA is 
involved in loss of adipose tissue in cancer cachexia at least in part due to its ability to 
inactivate PDC and thereby switch substrate oxidation in human adipocytes from 
glucose to lipids. 
In papers II and III, the role of LXR in human adipocyte function was studied, with 
focus on substrate oxidation (paper II) and lipolysis (paper III). In paper II, we treated 
human adipocytes with the LXR agonist GW3965 and observed an increased fatty acid 
and decreased glucose oxidation. We showed that LXR activation can increase the 
mRNA level of PDK4 and thereby the phosphorylation of PDC. We also showed a 
  
decreased activity of PDC, which was found to be dependent on PDK4. Furthermore, 
we could establish that the effect of GW3965 on lipid oxidation was specific for LXR, 
since it was abolished upon knockdown of LXR. In conclusion, we suggest that LXR 
has an important role in the regulation of substrate oxidation in human adipocytes, at 
least in part by influencing the phosphorylation status of PDC. 
In paper III, LXR activation was shown to up-regulate glycerol release from human 
adipocytes. Based on microarray analysis we found a strong impact of LXR activation 
on known lipolysis-regulating genes. We showed differences in expression and 
localization of perilipin 1 (PLIN1) and hormone sensitive lipase (HSL). When PLIN1 is 
depleted, the effect of LXR is abolished. Furthermore, we showed binding of LXR and 
its heterodimerizing partner Retinoid X Receptor to the promoters of HSL and PLIN1 
upon LXR activation. We also demonstrated that LXRα is the predominant isoform 
involved in regulation of adipocyte lipolysis within this context. In conclusion, we 
proposed that LXR activation up-regulates adipocyte lipolysis, at least in part through 
LXR binding to the promoter of PLIN1 and down-regulation of PLIN1 expression.  
 
In conclusion, we suggest that CIDEA and LXR can affect central functions of 
adipocyte metabolism, namely lipolysis and substrate oxidation. We show that CIDEA 
is involved in the loss of adipose tissue in cancer cachexia and that this is at least in part 
due to a shift in substrate oxidation. Activation of LXR in human adipocytes increases 
fatty acid oxidation and lipolysis, through effects on PDC and PLIN1. The findings in 
this thesis are of importance for conditions of dysregulated adipose tissue metabolism, 
such as obesity and cachexia. 
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1 INTRODUCTION 
The aim of this thesis is to investigate the role of two distinct factors – liver x receptor 
(LXR) and cell death-inducing DNA fragmentation factor-α-like effector A (CIDEA) 
in human adipocytes. Section 1 is a review of literature relevant for the studies and 
discussions in this thesis. I have summarized the most important concepts in studies of 
adipocytes and adipose tissue in the context of obesity and cancer cachexia. I have also 
reviewed published data on CIDEA and LXR in relation to adipocytes and adipocyte 
biology, focusing on human studies. 
 
1.1 OBESITY AND CACHEXIA 
Obesity is an excess of body fat as a result of an imbalance between energy intake and 
energy expenditure. In the last decade the incident of obesity has truly reached 
epidemic proportions. According to the world health organization (WHO), 1.5 billion 
adults were overweight in 2008, and of these around 500 million were obese. In 2010, 
nearly 43 million children under the age of five were overweight. Obesity is a 
multifactorial disease, influenced by both genetic and environmental factors. It is 
associated with adipocyte and adipose tissue dysfunction and, in turn, with severe 
health problems such as insulin resistance, type 2 diabetes, fatty liver, hypertension, 
dyslipidemia, atherosclerosis and cancer [1].  
 
On the other end of the spectra, cachexia is a syndrome manifested by involuntary 
weight loss. Cachexia is associated with cancer and non-malignant conditions such as 
tuberculosis, HIV, heart and renal failure and chronic inflammatory diseases such as 
rheumatoid arthritis and Crohn’s disease [2].  
 
1.1.1 ASSESSMENT OF BODY COMPOSITION 
Body mass index (BMI, weight in kg/(height in meters)2 ) is a measure used for 
classification of under- (<18.5 kg/m2), normal (18.6-24.9 kg/m2) and overweight (25 
kg/m2), see table 1. Individuals with a BMI over 30 kg/m2 are considered obese, and 
this definition is divided into three classes. The cut-off points for obesity and type 2 
diabetes are based on epidemiological data relating to risks of weight-related health 
problems, see table 1.  
 
TABLE 1. BMI CLASSES, DEFINED BY WHO 
Classification BMI (kg/m2) 
Underweight <18.5 
Normal weight 18.5-24.9 
Overweight ≥25 
Pre-obese 25-29.9 
Obese ≥30 
Obese Class I 30-34.9 
Obese Class II 35-39.9 
Obese Class III ≥40 
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BMI is the most used measurement of body composition. It is a simple and easily 
applicable method since it does not require specialized equipment, but also has some 
drawbacks. The BMI classification is inappropriate to use in certain groups of patients 
including children, elderly people and highly trained athletes. Other fairly simple 
methods that have won ground in the last few years and might be more appropriate are 
waist-to-hip ratio and waist circumference. More advanced methods, appropriate for 
clinical examinations but perhaps not larger population studies include dual energy X-
ray absorptiometry (DEXA) and bioelectrical impedance. Bioelectrial impedance can 
give an assessment of fat mass and fat free mass while DEXA provides data on fat 
mass, muscle mass and lean body mass.  
 
1.1.2 CANCER CACHEXIA 
Cancer cachexia, or unintentional weight loss concomitant with malignant cancer, is 
associated with a poor survival rate and an impaired response to chemotherapy [2, 3]. It 
is commonly defined as cancer with unintentional weight loss of >5% in the last 3 
months or >10% in the last 6 months. The weight loss affects both fat mass and lean 
body mass, however, the loss of fat mass often precedes and is more rapid than that of 
lean body mass [2, 3]. The mechanisms behind the adipose tissue (AT) loss are not 
completely clear, although increased lipid mobilization due to augmented adipocyte 
lipolysis seems to be a major contributing factor [3, 4]. Cancer patients with cachexia 
have a higher lipolytic rate, i.e. higher ratio of fatty acids or glycerol over fat mass, than 
cancer patients not suffering from cachexia [5, 6]. They also have higher levels of the 
important enzyme hormone sensitive lipase (HSL, described in detail in section 1.6.4) 
in their AT, indicative of an increased lipolysis. Furthermore, isolated subcutaneous 
(SC) adipocytes from cachexic patients display a higher catecholamine and natriuretic 
peptide-stimulated lipolysis in vitro compared to weight stabile cancer patients and 
noncancer patients. This effect could be counteracted by HSL-inhibition [5]. Also, the 
total lipase activity, the activity of both HSL and adipose triglyceride lipase (ATGL, 
described in detail in section 1.6.4), is higher in visceral (VISC) AT from patients 
suffering from cancer cachexia compared to weight-stable cancer patients [7].  
 
The size of adipocytes is also affected by cachexia as both human and murine cachexic 
adipose tissue is characterized by smaller adipocytes and also increased collagen-fiber 
content in the tissue matrix [8, 9]. Recent studies have shown that the decrease in AT 
mass in cachexia is due to a reduction of adipocyte volume and not adipocyte number 
[4, 10]. Global gene expression profiling of the molecular pathways associated with SC 
AT in cachexia indicates an up-regulation of pathways regulating energy turnover and a 
down-regulation of pathways concerning cell and tissue structure [10].  
 
1.2 THE ADIPOSE TISSUE 
The white adipose tissue (WAT) is a vital organ for mechanical cushioning, thermal 
insulation and energy storage and in the past it was believed that this was the only 
function of WAT. Recently it has become appreciated that WAT can act not only as 
metabolic organ but is also as an important endocrine organ. 
 
The WAT is the largest energy reservoir in the body and a major source of metabolic 
fuel [11]. Fat is stored in forms of triglycerides (TG) in the adipocytes and the WAT 
   3 
acts as a buffer by increasing clearance of TGs in plasma and suppressing the release of 
free fatty acids (FFA) into the circulation [11]. WAT is a loose connective tissue 
consisting of adipocytes and a stroma-vascular fraction (SVF), in turn containing 
preadipocytes, macrophages, lymph cells, mast cell, fibroblasts and endothelial cells. 
The mature adipocyte consists of a large lipid droplet occupying the major part of the 
cell. A layer of cytoplasm surrounds the lipid droplet and the nucleus is flattened and 
positioned to the periphery of the cell. In humans, there are two major fat depots: SC 
and VISC fat. The SC fat is less metabolically active compared to the VISC fat, and the 
differences in the regulation of the two depots will be discussed in section 1.6.1. In the 
recent years, another type of adipose tissue, the brown adipose tissue (BAT), has raised 
some interest in the obesity field after the discovery that BAT is present and active in 
adult humans and not only in rodents and infants, as previously believed [12-14]. The 
studies in this thesis, however, have only been performed in cells from and/or in WAT.  
 
The main function of the WAT is to store energy for periods of food deprivation and 
act as a mechanical shield and insulate the body, as mentioned above. The WAT is also 
an important endocrine organ secreting different factors, termed adipokines. The 
adipokines act in an auto and/or paracrine fashion and can thus regulate WAT and other 
organs such as muscle, liver and the central nervous system. According to recent data, 
there are over 250 proteins secreted from adipose tissue [15]. Two of the most well-
characterized adipokines are tumor necrosis factor-α (TNFα) [16] and leptin [17]. 
TNFα is a cytokine regulating a series of cellular and biological processes. In the 
context of WAT and obesity, TNFα is known to stimulate inflammation [16, 18] and at 
a cellular level, TNFα has been shown to stimulate human adipocyte lipolysis through 
reduction of phosphodiesterase 3B (PDE3B) [19, 20]. This pathway is described in 
section 1.6.3. TNFα can also reduce expression of genes important for insulin signaling 
[21] and fatty acid oxidation and uptake [22]. Leptin is an adipostat, which acts by 
signaling to the hypothalamus in the brain. Leptin is almost exclusively produced by 
adipocytes [17, 23] and promotes increased energy consumption while it reduces 
appetite and stimulates satiety [23, 24]. Leptin signals through the leptin receptor, LEP-
R, and mice lacking either the leptin gene (ob/ob) or the leptin receptor (db/db) are 
severely obese [17]. These mice are important model systems for the study of obesity 
and type 2 diabetes and humans with a dysfunction in the corresponding human genes 
display severe obesity [25]. Administration of recombinant leptin to humans or mice 
deficient in leptin restores body weight to normal levels by increasing metabolic rate 
and decreasing food intake [23, 26]. However, data from several studies indicate that 
there might be a general resistance to leptin in obesity. Circulating levels of leptin are 
directly correlated with adipose tissue mass; hence obese individuals have high levels 
of leptin in their circulation. Therefore, leptin treatment is not an effective way of 
treating common obesity. 
 
1.3 INSULIN AND INSULIN RESISTANCE 
Insulin is a protein synthesized in the β-cells of the islet of Langerhans in the pancreas 
and released into the circulation when blood glucose levels rise, e.g. in the postprandial 
state. When insulin binds to the insulin receptor (IR) on the surface of its target cells, 
several protein activation cascades are initiated, for example insulin receptor trans-
activation results in translocation of glucose transporter (GLUT) 4 to the plasma 
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membrane, leading to influx of glucose in the cell, glycolysis and glycogen synthesis. 
For a thorough review of insulin’s role in whole-body energy regulation, see 
biochemistry or physiology text books such as [27] or [28]. Insulin regulates WAT 
function on several levels: from uptake of FFAs into the adipocyte via lipoprotein 
lipase (LPL) to re-esterification, lipogenesis and lipolysis as well as GLUT4 
translocation. The role of insulin in regulation of lipolysis will be discussed in detail in 
section 1.6.3.  
 
Insulin resistance is a state when peripheral tissues become less sensitive to insulin and 
insulin actions. This leads to increased plasma glucose levels, which in turn leads to 
augmented production of insulin by the pancreas. When resistance persists, the insulin 
production becomes insufficient, resulting in hyperglycemia and type 2 diabetes [29]. 
The mechanisms behind the development of insulin-desensitization of the peripheral 
tissues are not completely understood, but it is known that circulating levels of FFAs 
are elevated in obesity due to an increased lipolysis, and the distribution of body fat is 
of importance. Increased levels of FFA in the circulation have been showed to have 
deleterious effects on peripheral tissues such as liver, muscle and pancreas and can 
affect insulin action, cell survival and glucose metabolism. A clinical study 
demonstrated that effects on insulin signaling, related to type 2 diabetes, occur as soon 
as four weeks after initiation of a high-calorie diet [30]. There is a strong connection 
between insulin resistance and the obesity-associated development of low-grade 
inflammation of the WAT, leading to increased FFAs and changes in adipokine release 
[31, 32].  
 
1.4 ADIPOSE TISSUE INFLAMMATION  
Obesity is associated with a chronic low-grade inflammation. This inflammation is 
tightly coupled to a dysregulation of AT, and the associated alterations change the 
release of adipokines and FFAs from the WAT, increasing the risk of obesity-
associated complications such as insulin resistance [24, 31-35]. Macrophages in the 
WAT are important regulators of the obesity-associated inflammation. Macrophages 
are a normal component of the cell population in the WAT, and in the non-obese state 
these are most probably scavenger cells involved in normal cellular turnover by 
clearing the tissue from apoptotic cells and lipids. These macrophages are termed M2-
macrophages and have anti-inflammatory properties. However, in the obese state, 
macrophage precursor cells are recruited from the circulation and these macrophages 
undergo polarization into a class of pro-inflammatory macrophages termed M1. The 
mechanism behind this polarization is unknown and heavily debated. The M1 
macrophages release high levels of pro-inflammatory cytokines such as TNFα and, in 
turn, stimulate lipolysis and inhibit insulin signaling [36-38].  
 
1.5 FATTY ACID OXIDATION 
When the body lacks energy in the fasted state, FFAs produced by lipolysis can be 
oxidized via mitochondrial β-oxidation. This process generates acetyl-CoA, the entry 
molecule for the tricarboxylic acid (TCA) cycle which, in turn, is a series of chemical 
reactions used by all aerobic living organisms to generate energy from carbohydrates, 
fats and proteins. The major site for β-oxidation is the skeletal muscle, although 
substrate oxidation in WAT is significant [39] and energy expenditure in human fat 
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cells is dramatically increased after body weight reduction [40]. Also, the capacity of 
human WAT to oxidize FFAs may change when the oxidative machinery is altered 
[41].  
 
Mitochondrial β-oxidation is regulated on several levels. Both the cellular uptake of 
FFA and the entry of acyl groups into the mitochondria are highly controlled. The latter 
is mainly regulated by the shuttle enzyme carnitine palmitoyl-CoA transferase (Cpt) I 
[42]. Also, the activity of the mitochondrial matrix enzymes, for example medium-
chain acyl-CoA dehydrogenase (MCAD) and 3-hydroxtacyl-CoA-dehydrogenase 
(HADHA) is of importance for the rate of mitochondrial β-oxidation [42].  
 
A key component in regulating the switch between glucose and fatty acids as fuel is the 
pyruvate dehydrogenase complex (PDC) [43]. The PDC catalyzes the oxidative 
decarboxylation of pyruvate, linking glycolysis (the breakdown of glucose) to acetyl-
CoA and nicotinamide adenine dinucleotide (NADH), which can then enter into the 
TCA cycle. The PDC is inhibited by a group of enzymes termed pyruvate 
dehydrogenase kinases (PDKs) via phosphorylation of the E1 component of the PDC 
(PDH-E1). Inhibition of the PDC results in a reduction of glucose oxidation and 
increase in fatty acid oxidation, since long chain fatty acids are favored over glucose as 
substrate. Four PDKs (termed PDK1-PDK4) have been identified in mammalian 
tissues. The regulation of the PDKs is complicated and multifaceted. Pyruvate 
inactivates PDK activity acutely while products of both the PDC reaction and β-
oxidation such as Acetyl-CoA and NADH are important for PDC inactivation in order 
to spare glucose during prolonged fasting. The different PDK-isoforms phosphorylates 
the PDC on different sites, leading to a dynamic regulation of fuel usage. PDK4, the 
most well studied isoform, has been shown to regulate oxidation in cardiac and skeletal 
muscle, kidney, liver and adipose tissue [44, 45] and its expression is regulated by the 
nuclear receptor peroxisome proliferator-activated receptor (PPAR)α.  
 
1.6 LIPOLYSIS AND LIPOLYSIS-REGULATION 
Lipolysis is the tightly regulated step-wise breakdown of TG to FFA and glycerol [46]. 
The first step (from TG to diglyceride, (DG)) is catalyzed by ATGL, the next step 
(from DG to monoacylglycerol, (MG)) by HSL and the final step is catalyzed by 
monoacylglycerol lipase (MGL) [47], see figure 1. HSL is capable of hydrolyzing all 
three steps, however it has the highest affinity for DAG. The efflux of FFA and 
glycerol from the adipocyte is followed by transport of these metabolites to other 
tissues, for FFAs mainly skeletal muscle, liver and heart and for glycerol, the liver. 
Some of the FFAs can remain within the adipocyte and be re-esterified to TGs. In non-
overweight humans, the mean turnover rate of TG in the fat mass is around 100-300 
g/day. There is a constant low level of lipolysis in adipocytes, termed basal or 
spontaneous lipolysis. Hormones can have a strong influence on the rate of lipolysis 
and inter-individual variations in AT lipolysis are of importance for the rate of weight 
loss [46]. The most important regulators of lipolysis-rate are catecholamines, natriuretic 
peptides (only in humans [48]) and insulin [46, 49].  
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Fig 1. A simplified schematic picture of the lipases controlling the hydrolysis of TG to FA and 
glycerol. ATGL; adipose triglyceride lipase, DG; diacylglycerol, FA; fatty acid, HSL; hormone 
sensitive lipase, MG; monoacylglycerol, MGL; MG lipase, TG; triacylglycerol 
 
1.6.1 CATECHOLAMINES 
Catecholamines are important regulators of the rate of lipolysis in human adipocytes by 
activation of adrenergic receptors (AR). In the cell membrane, an enzyme termed 
adenylyl cyclase (AC) resides, coupled to ARs via trimeric guanosine 5’-triphosphate 
(GTP)-binding proteins (G-proteins). In human adipocytes, three β-AR (β1, β2, β3) and 
one α-AR (α2A) have been identified [49]. Functional studies have shown that, among 
the β-receptors, β1 and β2 are most active while β3 seems to be more important in rodent 
fat cells. The β-receptors are coupled to G-stimulatory proteins activating AC, thereby 
increasing the production of the important cellular messenger cyclic adenosine 
monophosphate (cAMP). This activates the protein kinase A (PKA) complex, leading 
to phosphorylation and thereby activation of HSL and the lipid droplet coating protein 
perilipin 1 (PLIN1) [11, 49]. The α-receptors, however, are coupled to the G-inhibitory 
proteins leading to inactivation of AC. Catecholamines activate all four ARs in human 
adipocyte, and the balance between activation of α and β determines whether lipolysis 
is stimulated or inhibited. The stimulatory actions of β-ARs is however usually 
dominant [49]. A detailed schematic picture of lipolysis regulation is presented in 
Figure 2A. 
 
Obesity is characterized by an increased spontaneous lipolysis, partly due to increased 
adipocyte size, and a blunted stimulated lipolysis. However, there are some 
discrepancies between the two major fat depots. In the SC WAT from obese 
individuals, the expression of α2-AR is increased. At the same time β2-AR and HSL 
mRNA expression is decreased. This leads to a blunted stimulated lipolysis in obese 
SC WAT [49, 50]. However, in VISC WAT, β3-AR mRNA expression is increased 
while the levels of α2-AR are decreased, which results in an increased stimulated 
lipolysis [51]. FFA from the VISC fat has a stronger negative effect on other tissues, 
especially the liver. The VISC fat is drained to the liver via the portal vein. Therefore, 
FFAs from the VISC depot easily reach the liver, which can result in dyslipidemia, 
hyperinsulinemia, hyperglycemia and hepatic insulin resistance. Also, the release of 
FFA is stronger in the VISC depot due to a more pronounced effect of 
catecholamines and lower anti-lipolytic effect of insulin.  
 
1.6.2 NATRIURETIC PEPTIDES 
Besides catecholamines, natriuretic peptides can also contribute to an up-regulation of 
lipolysis. These effects are mediated via the natriuretic peptide receptor A (NPRA) and 
seem only to be present in humans. The receptor induces guanylyl cyclase, cyclic 
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guanylate monophosphate (cGMP) production, activation of protein kinase G (PKG) 
and finally HSL-phosphorylation [11, 49], see figure 2A. 
 
1.6.3 INSULIN 
Insulin is the most powerful endogenous inhibitor of lipolysis. Insulin binding to IR on 
adipocytes, starts a phosphorylation cascade involving the proteins insulin receptor 
substrates (IRS1 and -2) and the protein complex phosphatidyl inositol 3-kinase (PI3K). 
The PI3K-complex activates in turn protein kinase B (PKB) and PDE3B, catalyzing the 
breakdown of cAMP to its inactive form, 5’adenosine monophosphate (5’AMP). This 
leads to lower levels of cAMP and a decreased phosphorylation of HSL and PLIN1 
through PKA, see figure 2A. 
 
1.6.4 LIPASES 
As mentioned in the introduction to this section and as indicated in figure 1, there are 
three major lipases involved in the hydrolysis of FFA; ATGL, HSL and MGL. HSL 
was considered the key enzyme in adipocyte lipolysis for a long time. However, in 
2004, three groups independently reported that an enzyme capable of hydrolyzing TG, 
named ATGL (or desnutrin or phospholipase A2ξ) had been discovered [52-54].  
 
1.6.4.1 HSL 
HSL can hydrolyze both the first (from TG to DG) and second (from DG to MG) step 
in the lipolysis process (see figure 1), however the affinity of HSL in vitro is about 10 
times higher for DG, compared to TG [55]. HSL knockout mice are sterile and have 
enlarged adipocytes, both in BAT and WAT, but are not obese [55, 56]. Administration 
of an HSL inhibitor reduces plasma level of FFA in mice, rats and dogs, indicating that 
it has an important role in vivo [57]. Phosphorylation of HSL by PKA, at least on most 
Ser phosphorylation sites, leads to an increased activity of the enzyme. HSL activity is 
thereby controlled by catecholamines and insulin, since these factors can modulate 
levels of cAMP and thereby phosphorylation status of HSL. In rat HSL, three 
phosphorylation sites leading to increased activity have been characterized, Ser563, 
Ser659 and Ser660 [58], corresponding to Ser552, Ser649 and Ser650 in humans, 
respectively. HSL is also negatively regulated by phosphorylation on Ser554 
(corresponding to rat Ser565). According to a recent paper, Ser552 and Ser554 might be 
the most important sites in relation to lipolysis in human obesity [59].  
 
1.6.4.2 ATGL 
In mice, expression of ATGL is up-regulated by fasting and down-regulated in the 
postprandial state by insulin and TNF-α [60]. ATGL knockout mice have an increased 
body weight compared to wild type, and have more body fat. They accumulate fat in 
the heart and other tissues, leading to cardiac dysfunction [61]. However, they are 
glucose tolerant and insulin sensitive. In humans, several ATGL polymorphisms have 
been identified. These are associated with increasing circulating concentrations of FFA, 
TG and glucose and risk for type 2 diabetes, indicating that ATGL might be involved in 
the metabolic syndrome [62]. ATGL has been shown to be able to regulate basal 
lipolysis in humans [63]. However, ATGL is not regulated by obesity in humans, 
unlike HSL [64]. ATGL is also important for stimulated lipolysis. According to a 
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recent study in human adipocytes, ATGL was translocated from larger to smaller lipid 
droplets upon catecholamine stimulation. Furthermore, the stimulation increased the 
colocalization of ATGL and HSL [65]. The activity of ATGL requires the presence of a 
co-factor termed comparative gene identification 58 (CGI-58) [11].  In the unstimulated 
state, CGI-58 is bound to PLIN1 and thereby unable to activate ATGL. When the 
intracellular levels of cAMP rise, PLIN1 is phosphorylated, leading to dissociation of 
CGI-58 from PLIN1. CGI-58 is released from the lipid droplet, activates ATGL and 
thereby hydrolysis of TG [66-69]. The dynamic regulation of proteins on the surface of 
the lipid droplet is illustrated in Figure 2B.  
 
1.6.4.3 MGL 
The third lipase involved in TG hydrolysis in human adipocyte, MGL, is not 
hormonally regulated nor considered rate limiting, due to its abundance. To this end, it 
has not been the focus of many studies, compared to HSL and ATGL. However, a 
recent knockdown study indicates that MGL deficiency impairs lipolysis and attenuates 
diet-induced insulin resistance [70]. 
 
1.6.5 LIPID-DROPLET ASSOCIATED PROTEINS 
Since FFAs are highly toxic to cells, re-esterification of FFAs into TGs is vital for cell 
survival. Within cells, TGs are stored in lipid droplets. The lipid-droplet coating 
proteins protect cells from the deleterious effects of FFA and are also important for the 
regulation of lipolysis when the fat is needed as energy. There are several lipid-droplet 
associated proteins and below I will describe two of the most important ones, PLIN1 
and cell-death inducing DNA fragmentation factor, α subunit-like effector C (CIDEC). 
 
1.6.5.1 PLIN1 
The predominant protein family for lipid droplets is the PLIN family, and in adipocytes 
PLIN1 is the main factor. PLIN1 is the most highly phosphorylated protein in 
adipocytes and is essential for lipolysis [11]. Low levels of PLIN1 are associated with 
increased basal lipolysis and attenuated stimulated lipolysis in both rodents [71, 72] and 
humans [73]. Genetic ablation of PLIN1 gives a lean phenotype and resistance to diet- 
or genetically induced obesity in mice [71, 72]. It also affects lipid oxidation and 
biosynthesis, not only in AT but also other peripheral tissues such as liver, skeletal 
muscle and kidney [74]. PLIN1 has a dual role in regulation of lipolysis. In the basal 
state, PLIN1 probably works as a barrier, protecting the TGs from hydrolysis. As 
described above and in Figure 2B, when PLIN1 is phosphorylated by PKA, CGI-58 is 
released, activating ATGL and thereby lipolysis. Also, PKA-phosphorylation of PLIN1 
causes a conformational change of the protein, leading to recruitment of phosphorylated 
HSL to the lipid droplet surface and increased lipolysis [75]. 
 
1.6.5.2 CIDEC 
Another important lipid droplet-associated protein regulating lipolysis is CIDEC [76]. 
CIDEC is predominantly expressed in adipocytes from the SC depot and is down-
regulated in response to caloric restriction [77]. Down-regulation of CIDEC by siRNA 
has been shown to increase lipolysis and decrease the size of lipid droplets in 3T3-L1 
adipocytes [77, 78]. Also, cells lacking CIDEC are less responsive to adrenergic 
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stimulation of lipolysis [77], further indicating a possible role for CIDEC in lipolysis 
regulation and lipid droplet biology. CIDEC belongs to the CIDE-proteins, and 
CIDEA, the major protein studied in paper I, will be discussed in detail below. 
 
 
Fig 2 A: Lipolysis regulation in human adipocytes. B: Changes on the lipid droplet surface upon lipolysis 
activation. AR, adrenergic receptors; AC, adenylyl cyclase; AMP, adenosine monophosphate; ATGL, 
adipocyte triglyceride lipase; ATP, adenosine 5’-triphosphate; cAMP, cyclic AMP; CGI-58, comparative 
gene identification-58; cGMP, cyclic guanosine monophosphate; CIDEC, cell death-inducing DNA 
fragmentation factor-α-like effector C; DG, diacylglycerol; Gi/s, inhibitory/stimulatory GTP-binding 
protein; GC, guanylyl cyclase; GTP, guanosine triphosphate; HSL, hormone sensitive lipase; IR, insulin 
receptor; IRS, IR substrate; MG, monoacylglycerol; MGL, MG lipase; NPRA, natriuretic peptide 
receptor A; PDE3B, phosphodiesterase 3B; PLIN1, perilipin 1; PKA, protein kinase A, PKG, protein 
kinase G; TG, triacylglycerol 
 
1.6.6 ZINC-α2-GLYCOPROTEIN (ZAG) 
 
Zinc-α2-glycoprotein (ZAG) has been considered a candidate molecule responsible for 
the activation of lipolysis in cancer cachexia. ZAG is a protein expressed and secreted 
by several normal tissues however over-expressed in several types of tumors. It can 
stimulate lipolysis in both rodent and human fat cells, at least in vitro. Furthermore, AT 
from patients suffering from cancer cachexia has an increased gene expression and 
secretion of ZAG. This secretion is also proportional to the degree of weight loss [9]. 
However, a recent paper suggests that ZAG is activated in the AT by the catabolic state 
when the need for energy-rich lipids is high. The ZAG protein is not secreted but acts 
locally to up-regulate lipolysis and is an effect of the catabolic state per se, rather than 
the cancer cachexia [79]. 
 
1.7 CIDEA 
CIDEA belongs to a family of apoptotic proteins termed the CIDE-proteins [80]. The 
most important family members in the context of this thesis are, except for CIDEA, 
CIDEB and CIDEC. These three proteins show high sequence similarity but different 
tissue expression, CIDEB is expressed in human liver and small intestine and murine 
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liver while CIDEC is expressed in human heart, small intestine and liver and human 
and murine WAT.  
 
In our laboratory, we came across CIDEA in a microarray where the mRNA of this 
gene was down-regulated in WAT of obese subjects, and up-regulated upon weight loss 
[81, 82]. Also, it was shown that CIDEA could regulate lipolysis [82]. Since then, in 
work from our group, a single nucleotide polymorphism (SNP) in CIDEA has been 
associated with obesity [83], the human promoter of CIDEA has been described [84], 
and in paper I, we propose a role for CIDEA in cancer cachexia.  
 
1.7.1 ROLE OF CIDEA IN ADIPOCYTES 
There appears to be a clear discrepancy between the role of CIDEA in mice and 
humans. CIDEA is highly expressed in murine BAT and is lowly expressed in murine 
WAT [80, 85-87]. Mice lacking CIDEA are lean and resistant to diet-induced obesity. 
They show an increased metabolic rate, probably due to increased protein levels and 
activity of 5’AMP-activated protein kinase (AMPK) in BAT, combined with an 
increased β-oxidation in brown adipocytes [87, 88]. However, in humans, CIDEA is 
almost exclusively expressed in WAT. Obese humans have a lower expression of 
CIDEA in WAT compared to lean [81, 82, 89], and CIDEA was the most up-regulated 
protein in human SC WAT following diet-induced weight loss [82] in a Swedish 
cohort. Furthermore, low CIDEA expression is associated with several features of the 
metabolic syndrome, and RNAi-mediated depletion of CIDEA in human adipocytes 
increased lipolysis and TNF-α-secretion [82]. There is also a coding SNP in the human 
CIDEA gene associated with obesity [82, 83]. Taken together, this indicates that 
CIDEA might be important for the regulation of fat mass in human adipocytes.  
 
1.7.2 LOCALIZATION OF CIDEA IN ADIPOCYTES 
There has been controversy about the localization of CIDEA in fat cells. Several reports 
have shown that both endogenous and ectopically expressed CIDEA can localize to the 
lipid droplet, affecting lipid storage [90-92]. In brown adipocytes, ectopically expressed 
CIDEA was detected on the endoplasmatic reticulum [88]. A recent paper from our 
group indicates that CIDEA is localized to both the cytoplasm and the nucleus of 
human white fat cells. In the same paper, it is shown that CIDEA can regulate LXR 
[93]. This will be discussed further in section 5. In paper I, we show that CIDEA is 
involved in adipose tissue loss in cancer cachexia, at least in part by inactivation of 
PDC and thereby allowing a switch in substrate oxidation from glucose to fat in human 
adipocytes.  
 
1.8 LXR 
1.8.1 INTRODUCTION TO NUCLEAR RECEPTORS AND LXR 
LXRs are transcription factors belonging to the nuclear receptor super family. Nuclear 
receptors (NR) are a class of ligand-activated transcription factors involved in 
numerous biological processes. NRs exert their transcriptional regulation through direct 
binding to DNA and through interaction with multiple coactivator or corepressor 
complexes. This leads to modifications of chromatin environment and alters 
transcription of target genes. NRs have a common modular structure and consist of the 
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following domains: N-terminal regulatory domain, DNA-binding domain, hinge region, 
ligand-binding domain and C-terminal domain. An important aspect of NRs is their 
ability to activate or repress gene transcription by binding of a ligand, for example 
hormones, vitamins, lipid metabolites or drugs. This feature makes the NRs attractive 
potential drug targets. For a review on nuclear receptors in general, see [94].  
 
LXRs have in the last 15 years been identified as important metabolic regulators in 
many tissues and cell types. Upon activation, they bind DNA at specific sites termed 
LXR response elements (LXREs) as heterodimers with the retinoid x receptor (RXR) 
(for a review on RXR, see [95]) and affect the transcription of their target genes. The 
most well studied aspects of LXR regulation are their role in cholesterol metabolism 
and atherosclerosis. For a review on LXR, see [96] and figure 3. This thesis will focus 
on the role of LXR in adipose tissue and adipocytes.  
 
Both isoforms of LXR, LXRα and LXRβ - coded by the NR1H3 and NR1H2 genes, 
respectively, are expressed in mature murine and human adipocytes. LXRβ is 
ubiquitously expressed, while LXRα is predominantly expressed in WAT, liver, small 
intestine and macrophages [97] and is up-regulated during adipocyte differentiation. 
The expression of LXRβ is not changed during adipogenesis. A study from our group 
has showed that obese women have higher levels of LXRα in SC WAT compared to 
lean. Also, SNPs in both isoforms are associated with obesity [98]. Three different 
splicing forms of LXRα have been identified, however the role of these is still not clear 
[99]. LXR was first discovered as an orphan receptor, a receptor without an identified 
ligand, but was deorphanized with the discovery of the oxysterols as the natural ligand. 
LXR is important for several aspects of adipocyte metabolism, however the role of 
LXR in regulation of important adipocyte functions such as adipogenesis and 
lipogenesis is still a matter of debate.  
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Figure 3 Summary of functions attributed to LXR in different cell types. The proposed roles of LXR 
in different cellular processes are summarized for macrophages, brown and white adipocytes. Where 
available, information on the main receptor-isoform (i.e. α or β) mediating the effect is indicated. Positive 
(↑), negative (↓) or no (-) effects following LXR activation are indicated as reported in the literature. 
Figure from Laurencikiene and Rydén, submitted. 
 
1.8.2 LXR AND ADIPOGENESIS 
The reports concerning LXR and adipogenesis, the process of cell differentiation by 
which preadipocytes become adipocytes, are inconclusive. A central question is the 
potential crosstalk between LXR and a master regulator of adipogenesis, PPARγ. 
Different studies have reported that LXR ligands can suppress, activate or not at all 
affect adipogenesis. As mentioned above, LXRα is up-regulated during adipocyte 
differentiation in vitro. This induction is mediated by the indispensible adipogenic 
genes PPARγ and CCAT/enhancer-binding protein α (C/EBPα), at least in human in 
vitro differentiated Simpson-Golabi-Behmel syndrome (SGBS) preadipocytes and 
murine 3T3-L1 cells [100-102]. Also, several treatments interfering with adipogenesis, 
such as ultraviolet light A, flavonoids and some polyunsaturated fatty acids, cause a 
simultaneous down-regulation of LXRα and PPARγ [103, 104]. Pioglitazone (a PPARγ 
activator) treatment of non-diabetic subjects has been shown to up-regulate LXRα 
mRNA expression [105]. The potential crosstalk between PPARγ and LXR is even 
more complex since both PPARγ and some of its target genes, for example the fatty 
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acid binding protein aP2, are in turn LXRα target genes in adipocytes [106, 107]. 
Several previous reports have shown that LXR activation during adipogenesis, a 
process heavily driven by PPARγ, can potentiate fat accumulation in both human and 
murine cells [100, 107], and siRNA-meditated knockdown of LXRα suppresses 
adipocyte differentiation, however only in mice expressing PPARγ [107]. Other studies 
show no or even a negative effect of LXR on adipogenesis [108, 109]. Even though 
LXR could act as a modulator of adipocyte differentiation, it is not essential for murine 
adipogenesis since LXRαβ-/- mice have functional, although somewhat reduced AT 
[110, 111]. 
 
1.8.3 LXR AND CHOLESTEROL TRANSPORT IN ADIPOCYTES 
One of the most well studied functions of the LXRs is their ability to regulate 
cholesterol transport and metabolism by up-regulation of important cholesterol 
transporters in liver, intestine and macrophages. LXR can also up-regulate the 
expression of the rate-limiting enzyme in bile acid synthesis, Cyp7 (only in mice), and 
the HDL-associated lipoprotein E (ApoE) [112]. In murine adipocytes, LXR has been 
shown to induce expression of several genes related to cholesterol metabolism, for 
example ApoE [113, 114], and LXR activation leads to an increased expression of both 
the cholesterol transporters ABCG1 and A1 and ApoE in wild type mice, but not mice 
lacking LXR. In papers II and III, we have used up-regulation of ABCG1 as a control 
for proper LXR activation. 
 
1.8.4 LXR AND LIPOGENESIS 
In the liver, activation of LXR both via endogenous and synthetic agonists induces 
lipogenesis. This is mediated via up-regulation of SREBP1c and its response genes, for 
example fatty acid synthase (FAS) and steoryl-CoA desaturase 1 (SCD1) [97]. In 
adipocytes, the role of LXR is less clear due to conflicting data from different 
laboratories. However, taken together the data speaks against a major role for LXR in 
lipogenesis in human and murine adipocytes. Mice lacking LXR have smaller fat 
depots [111] and an increased expression of FAS in WAT [110, 115], indicating a role 
for LXR in lipogenesis. Furthermore, treatment with LXR ligand of 3T3-L1 adipocytes 
during differentiation has been shown to increase the expression of FAS and SREBP1c, 
and up-regulate lipid accumulation [100, 107]. A different study indicated that the LXR 
ligand T0901317 up-regulated FAS and SREBP1c in murine AT in vivo [107]. 
Conversely, stimulation of human primary adipocytes with LXR agonist for 7 days in a 
different study only marginally affected the expression of SREBP1c, FAS and SCD1 
[116]. Also, LXR activation has been shown to induce up-regulation of SREBP1c in 
3T3-L1 cells, but without SREBP1c recruitment to the FAS promoter or induction of 
activity of a FAS promoter-driven reporter gene. As a result, there was no effect on 
FAS after LXR activation, despite up-regulation of SREBP1c [117]. Different cell 
culture conditions and experimental setup, such as time-point of LXR stimulation, 
could explain at least a part of these discrepancies. It is also worth mentioning in this 
context that human adipocytes in general display a very low level of de novo 
lipogenesis. 
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1.8.5 LXR AND LIPOLYSIS 
LXR has been shown to increase the degree of basal lipolysis in several studies. The 
basal release of FFA was increased in murine 3T3-L1 cells with over-expressed and 
activated LXRα, and administration of the LXR agonist T0901317 to mice led to 
increased serum FFA and glycerol [108], indicating an increased lipolysis. 
Furthermore, a similar treatment with another LXR agonist, GW3965, resulted in 
smaller adipocytes [118], also indicating increased lipolysis. In paper III, we show that 
stimulation with GW3965 increased basal lipolysis in both human and murine 
adipocytes in culture. We also show that this is at least in part mediated by binding of 
LXR to the promoter of PLIN1, leading to decreased levels of PLIN1. 
 
The role of LXR in hormone-stimulated lipolysis is puzzling. In 3T3-L1 cells with 
over-expressed LXRα, treatment with LXR agonist did not change the maximal rate of 
FFA or glycerol release upon stimulation with an agonist for the β3-adrenoreceptor 
[108]. However, isolated adipocytes from LXRαβ-/- mice have been shown to display 
a three times higher maximal response to noradrenalin stimulation (acting as a non-
selective α- and β-adrenoreceptor activator), compared to adipocytes from wild-type 
littermates [110]. Also, the microarray data presented in paper III indicate that several 
genes known to affect stimulated lipolysis are influenced by LXR activation in human 
adipocytes. However, only LXRs effect on basal lipolysis is studied in paper III. 
 
1.8.6 LXR AND LIPID OXIDATION 
Activation of LXR has been shown to up-regulate skeletal palmitate oxidation [119] 
and cardiac expression of PDK4 [120]. Furthermore, administration of an LXR agonist 
to mice caused an increase in hepatic peroxisomal β-oxidation and up-regulated MCAD 
and HADHA [121]. Also, LXR-KO mice show increased FFA synthesis and energy 
consumption in WAT, indicating that LXR might be important for energy homeostasis 
[115]. Interestingly, LXR has been implicated in the negative regulation of oxidation 
and energy expenditure in brown adipocytes [122, 123]. In paper II, we show that 
activation of LXR in white human and murine adipocytes up-regulates fatty acid 
oxidation and down-regulates glucose oxidation. This is, at least in part, mediated by 
PDK4-dependent phosphorylation of the PDC, shifting the fuel usage from glucose to 
fatty acids. 
 
1.8.7 LXR-KNOCKOUT MICE 
Even though there is still no data on adipose tissue-specific LXR-knockout mice, a lot 
can be retrieved in this area from the double and isoform-specific LXR knockouts that 
have been described. LXRαβ-/- mice are glucose tolerant and insulin sensitive. They 
have 15-20% smaller AT depots compared to their wild type littermates, a discrepancy 
that increases with age [100, 115]. LXRαβ-/- mice are resistant to diet induced obesity, 
probably due to an increased metabolic rate, and have smaller adipocytes compared to 
wild type [111, 115, 124]. WAT from knockout mice have higher expression levels of 
both PLIN1 and HSL, compared to wild type littermates [110]. There appears to be a 
difference with regards to the energy-expenditure regulation, two studies show 
increased expression of uncoupling protein 1 (UCP1) in muscle and AT from LXRαβ-
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/- mice [115, 122] while in another study, UCP1 is increased in BAT [123] but not 
WAT [124]. 
 
1.8.8 LXR ISOFORMS 
As mentioned above, the LXR isoforms display different tissue distribution patterns. 
Gene expression profiling in gonadal WAT from isoform-specific knockouts, compared 
to wild type, shows that a similar number of genes, around 400, are positively or 
negatively affected by knockdown of LXRα. However, only 155 genes are up-
regulated by LXRβ knockdown, compared to 328 down-regulated genes [125]. 
Analysis of gene ontology indicates that while genes related to carbohydrate 
metabolism are more LXRα-specific, genes coding for cytokines was higher regulated 
by LXRβ. The cholesterol transporters are equally regulated by both isoforms [114, 
126]. Mice lacking LXRα were similar to wild type concerning fat accumulation on 
high fat-diet, however they remained insulin sensitive and had an increased expression 
of UCP1 [111, 122, 124]. Mice lacking LXRβ, on the other hand, were resistant to diet-
induced obesity, had smaller fat cells and impaired fat storage in adipocytes, similar to 
the LXRαβ-/- mice [111, 124]. This indicates that the LXR isoforms might have 
diverse roles in the regulation of metabolism. In paper III, we show that up-regulation 
of lipolysis by LXR activation is an effect mainly dependent on LXRα and not LXRβ. 
 
1.8.9 LXR CO-FACTORS 
Since the LXRs are nuclear receptors ligands, NR dimerization partners and 
transcriptional co-regulators regulate their transcriptional activity. LXRs associate with 
NR Co-repressors (NCoR), Silent Mediator of Retinoic acid receptor and thyroid 
receptors (SMRT) and small heterodimer partner (SHP) [127-129], but direct 
interaction with either of these proteins and LXR has not been shown in adipocytes. 
However, both LXRα and β have been shown to interact with receptor-interacting 
protein 140 (RIP140) [130, 131]. Furthermore, a recent paper from our group show a 
direct interaction between LXR and CIDEA [93].  
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2 AIMS 
 
The aim of this thesis was to investigate how LXR and CIDEA can affect important 
aspects of adipocyte metabolism. Further knowledge on the regulation of adipocyte 
metabolism and its regulators could be of great importance in future treatments of states 
of AT dysfunction, such as obesity and cachexia. 
 
I. The aim of paper one was to study the role of CIDEA in relation to fat loss in 
cancer cachexia 
II. The aim of the second paper was to investigate the effect of LXR on substrate 
oxidation in human adipocytes  
III. The studies in the third paper aimed at examining the role of LXR in relation to 
basal lipolysis in human adipocytes 
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3 COMMENTS ON MATERIALS AND METHODS 
 
The experimental methods used in the papers included in the thesis have been described 
in detail in the respective papers. In this section I will briefly describe some of the 
techniques and their advantages and/or disadvantages compared to alternative methods. 
 
3.1 SUBJECTS AND ADIPOSE TISSUE SAMPLE COLLECTION 
All studies were conducted in accordance with the guidelines of the Declaration of 
Helsinki and approved by regional ethical committees at Karolinska University 
Hospital. Written consent was obtained from all participants. For paper I, all patients 
scheduled for gastrointestinal cancer operations between January 2004 and December 
2005 were evaluated, selections were made and subjects were divided into groups 
based on diagnosis after surgery. Details on exclusion and inclusion are described in 
detail in the paper. Around 450 patients were evaluated. Patients who were fit in spite 
of their cancer, had not received prior anti-cancer treatment and were willing to 
participate were included, n = 48. The patients were then divided into three groups 
based on the diagnosis after surgery: 
 
Cancer cachexia (n = 23): gastrointestinal cancer with unintentional weight loss of >5% 
in the last 3 months or >10% in the last 6 months.  
Weight-stable cancer (n= 17): patients with gastrointestinal cancer who reported no 
important weight change during the last year. 
Control group (n = 8): patients with pre-diagnosed gastrointestinal cancer but who did 
not have a malignancy according to final histological evaluations. 
 
It should be noted that all of the cancer patients included in the study suffered from 
gastrointestinal cancer, which should be taken into consideration when evaluating and 
interpreting the results from the study. Also, a large proportion (75%) of the patients is 
male and of fairly high age. However, since gastrointestinal cancer is more common in 
men and in older patients, this factor is difficult to circumvent. All studies have been 
performed in SUC WAT since we did not have access to VISC WAT from these 
patients. 
 
For the molecular studies in all three papers, SC adipose tissue was obtained from 
healthy subjects undergoing cosmetic lipoaspiration. They were not selected for age, 
sex or body weight.  
 
3.2 CELL CULTURE 
The use of different in vitro systems such as cell lines and primary cultures are essential 
to the type of research performed in this thesis. For the molecular studies we have used 
primary cultures of human in vitro differentiated adipocytes whenever possible, and 
used the murine cell line 3T3-L1 as a complimentary system to see potential species 
differences, or when technical problems made it difficult to use primary human cells.  
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At present, there is no readily available, well-working cell line of human adipocytes. 
Therefore, either primary human adipocytes or the murine cell line 3T3-L1 is often 
used. Unfortunately, this approach has several drawbacks. Cell lines in general have 
changes in the cell cycle machinery, making them easy to work with since they can be 
frozen and thawed whenever needed. Also, every passage is identical to the previous 
ones, giving high reproducibility. However, the changes in cell cycle machinery gives 
an altered phenotype of the cells and makes them more prone to spontaneous 
mutations, compared to primary cell cultures. 3T3-L1 cells are of murine origin, raising 
questions about species differences. However, the primary cell cultures also have 
drawbacks. There might be higher individual variation, depending on the individual 
donors, the supply is unpredictable and they seem to be sensitive to infections. Also, 
isolating and culturing the primary adipocytes is a time-consuming task. 
 
In the papers in this thesis, 3T3-L1 cells were cultured and differentiated to adipocytes 
using a standard protocol [132]. The in vitro differentiated human adipocytes were 
isolated, cultured and differentiated as previously described [133, 134]. In brief, WAT 
was cut into small pieces, digested with collagenase and centrifuged. The stroma-
vascular fraction was resuspended and filtered after which the cells were plated in 
inoculation media. After 24 hours the medium was changed to differentiation media, 
containing Dulbecco’s modified eagle’s medium (DMEM)/F12 with fetal bovine 
serum, penicillin-streptomycin, amphotericin B, human insulin, triiodo-L-thyroine, 
human transferring, biotin, panthotenate, cortisol and rosiglitazone. The rosiglitazone, a 
PPARγ agonist, was present for the first 3-6 days and then removed. After 
differentiation, around 70% of the preadipocytes displayed a round shape with a 
completely filled cytoplasm. Plates with less than 70% differentiation density were 
discarded.  
 
3.3 OVER EXPRESSION OF CIDEA 
In paper I, human CIDEA (hCIDEA) was over-expressed in murine 3T3-L1 cells and 
in vitro differentiated human adipocytes, since these cells express very low endogenous 
levels of CIDEA. The CIDEA expression vector was obtained by insertion of hCIDEA 
into a plasmid. Constructs were verified by sequencing and protein expression was 
confirmed using in vitro translation. For the transfections, Lipofectamine and Plus 
Reagent were used after careful optimization of transfection conditions, using green 
fluorescent protein-containing plasmids. The efficiency of transfection was around 
40%.  
 
3.4 FATTY ACID OXIDATION 
In papers I and II, palmitate oxidation was assessed in in vitro differentiated human 
adipocytes and 3T3-L1 cells. As described in the introduction, β-oxidation supplies the 
cells with fuel for the TCA cycle. In this method, cells are fed 14C-labeled palmitate and 
the amount of 14CO2 and 14C-labeled metabolites, side products of the TCA cycle, are 
measured. The rate-limiting factor carnitine was supplied in excess and a powerful 
stimulator of β-oxidation was used as a positive control.  
 
When assessing substrate oxidation in vivo, calculation of respiratory quotient (RQ) is 
a common method. It is calculated from removal of carbon dioxide and consumption of 
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oxygen and results in a unit less number reveling the major energy source. An RQ of 1, 
for example, represents pure carbohydrate oxidation and a number around 0.7 indicates 
that fat is the major substrate for oxidation in the patient. This method is used in paper 
I. 
 
3.5 GLUCOSE OXIDATION 
In papers I and II, glucose oxidation was also assessed. The method is similar to the 
fatty acid oxidation method described above; however labeled glucose is added to the 
cells instead of palmitate. Radioactive CO2 was collected and measured by scintillation 
counting. 
 
3.6 ACTIVITY AND PHOSPHORYLATION OF PDC 
An important part of both papers I and II was the experiments showing differences in 
phosphorylation status and/or activity of the PDC. As described above, PDC acts as a 
cellular fuel switch, regulating if glucose or FFAs are the primary energy source for the 
TCA cycle. When PDC is inactivated by phosphorylation, glucose oxidation is 
inhibited in favor of lipid oxidation. In papers I and II we used a PDC pull-down kit 
based on the immunoprecipitation technique. Protein lysates from 3T3-L1 cells and/or 
human in vitro differentiated adipocytes were immunoprecipitated using an anti-PDH-
E1 antibody coupled to Sepharose beads. The E1 subunit is the subunit phosphorylated 
when PDC is inactivated. After washing and elution, the proteins were separated by 
SDS-PAGE and transferred to a membrane. An anti-phosphoserine antibody was used 
for detection. In the studies, two different controls for equal loading were used for 
technical reasons. In the murine experiment, and also in paper I, we used the anti-
phosphoserine antibody to detect levels of input material as a loading control, a 
standard way of assessing equal loading when performing IPs. However, a better 
control is measurement of total amount of PDC-E1, and then relating this to the amount 
of phosphorylated PDC-E1. This was used in the experiments performed in the later 
part of the study, namely the human adipocytes. 
 
In paper II, we confirmed the increased phosphorylation of the PDC by showing 
decreased activity of the complex. This was performed using a then novel ELISA-based 
technique utilizing the lateral flow concept. Antibodies are captured onto nitrocellulose 
membranes on the dipstic, and a wicking pad draws the protein lysate through the 
antibody band. The intensity of the bands represents the activity of the complex, since 
the PDH activity reaction produces NADH. NADH, in turn, is coupled to the reduction 
and precipitation of a colored dye, showing on the dipstick as a band. 
 
3.7 LIPOLYSIS 
In paper III, lipolysis was assessed as release of glycerol from in vitro differentiated 
human adipocytes and murine 3T3-L1 cells. Lipolysis is, as described above, a process 
where TG are hydrolyzed to three FFA and one molecule of glycerol. Since FFA can be 
utilized within the adipocyte in a process termed re-esterification, lipolysis is 
preferentially measured as release of glycerol, and not of FFA, into the cell culture 
media. The method used to assess the levels of glycerol in paper III is a 
bioluminescence method based on luciferase, luciferine, glycerol kinase and ATP [135-
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137]. Two competing reactions, one catalyzed by glycerol kinase and one by luciferase 
compete for the available ATP. A higher concentration of glycerol in the sample will 
decrease the amount of light emitted. This light is measured in a luminometer and 
glycerol levels are calculated, based on a standard curve with known glycerol 
concentrations. 
 
3.8 GENE EXPRESSION  
In all three papers, quantitative real-time polymerase chain reaction (RT-qPCR) is used 
to assess mRNA levels of specific genes. The mRNA levels of a gene can often reflect 
protein levels of the respective gene in the cells. In the PCR reaction, certain sequences 
are amplified using specific primers and enzymes and the reaction is monitored in real-
time using a PCR machine. This instrument measures the amount of PCR product, 
based on fluorescence, in the reaction. Fluorescence is generated in each PCR cycle and 
this amount is directly proportional to the amount of PCR product in the reaction. In the 
papers in this thesis, two different detection methods have been used: SYBR green and 
Taqman. 
 
SYBR green is a non-specific dye that fluoresces only when bound to double-stranded 
DNA. SYBR green is a less specific, however simpler and cheaper method of detecting 
amount of PCR product in the samples. There is a risk for false-positive results since 
the dye detects not only specific products but also primer-dimers and unspecific 
products. However, this problem can be avoided with careful primer design and the use 
of dissociation curves and agarose gel electrophoresis, making sure that a single 
product is obtained.  
 
The Taqman assays, purchased from the manufacturer, contain fluorescent-labeled 
probes complementary to a sequence in the target gene. The probes are labeled with a 
flourophore and a quencher, absorbing the fluorescence when the probe is unbound. 
The target-bound probe is degraded by the Taq polymerase during elongation, releasing 
the flourophore from the quencher. This emits fluorescence. Taqman is a more 
sensitive detection method than SYBR green but the method has its drawbacks. It is 
more expensive, requires more material (in our setup it requires twice the amount of 
cDNA as SYBR green) and is dependent on that a probe for your gene of interest is 
available.   
 
The results of the PCRs, independent of detection method, are Ct-values. This value 
represents the point in the reaction when the fluorescence reaches above the threshold 
value, due to the amplification. There is a linear relationship between the log of the 
starting amount in the sample and their corresponding Ct. We have used the 2-ΔΔCT 
comparative method to determine the mRNA levels of the different genes [138].  
 
When running RT-qPCR it is essential to use reliable reference genes or “house-
keeping” genes, genes not affected by the experimental conditions. These genes are 
amplified in parallel reactions. We have used several different reference genes and 
compared the results between them, making sure that we get similar relative results 
independent of reference gene. Two of the reference genes used are 18S rRNA and 
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LRP10, the latter one a gene previously shown to be a dependable reference gene for 
human WAT [139].   
 
3.9 RNAI 
In papers II and III, RNA interference (RNAi) was utilized to silence expression of 
different genes using small interfering RNA (siRNA). In this method, small double 
stranded RNA molecules are transfected into primary cell cultures, interfering with the 
expression of a specific target gene. For technical reasons, siRNA from two different 
companies, Qiagen and Dharmacon, where purchased and used in paper II. In paper III, 
only siRNA from Dharmacon was used since this company provides a pool of four 
different siRNAs targeting different sequences in the same mRNA, resulting in a better 
knockdown. As a negative control, we used non-targeting siRNA from the respective 
company. The non-targeting siRNA have no known similarities to human sequences. In 
the supplemental data of paper II, we performed extensive methodological experiments 
indicating that the control oligonucelotides do not cause any important off-target effects 
in our system. We also show that siRNA treatment against a housekeeping gene does 
not influence lipolysis. 
  
3.10 MICROARRAY  
The RNA used for the microarray was carefully quality-checked and the array was run 
according to standard protocols by the core facility at Karolinska Institutet, Stockholm, 
Sweden. For the analysis of differences in expression of individual genes on the 
microarray between LXR activated and vehicle-treated samples, the data set was 
normalized using probe logarithmic intensity error (PLIER). The normalized data set 
was then analyzed using significance analysis of microarrays (SAM) with a false 
discovery rate of 1%. For table I in paper III, a list of genes that could be of importance 
and that had an absolute call over 150 and genes known to regulate lipolysis in 
adipocytes (even genes or genes with a lower absolute call) was compiled and it was 
indicated whether these were significant according to SAM or not. All genes that we 
studied further were confirmed using qRT-PCR.  
 
3.11 PROTEIN MEASUREMENTS 
In all three papers, Western Blot was used to quantify amount of protein in samples of 
different treatments. Western Blot is a standard technique of verifying the identity of 
protein using antibody recognition and size, and the migration of denatured proteins 
compared to a known standard scale is assessed. The detection method used in the 
present papers is chemiluminiscence and the intensity of the bands was quantified using 
the Quantity-One software. The selection of specific and efficient antibodies is vital to 
obtain good results when using Western Blot, and all antibodies were carefully tested. 
In the case of HSL in paper III, we used two different antibodies, both giving similar 
results.  
 
3.12 CHROMATIN IMMUNOPRECIPITATION (CHIP) 
ChIP is an assay based on the interaction between chromatin and transcription factors 
and was used in paper III to show direct binding of LXR to the promoters of PLIN1 and 
HSL upon activation of LXR. The DNA-protein-complexes are crosslinked, isolated 
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and sonicated to smaller fragments. The fragments are then immunoprecipitated using 
an antibody, in this case against LXR, after which the DNA was extracted and analyzed 
using qRT-PCR with specific primers against sequences in the promoters of PLIN1, 
HSL and, as a control, the known LXR target gene ABCG1. ChIP is a specific method 
and is very useful in the study of transcription factors such as LXR. The biggest caveats 
are the necessity of a specific antibody and that large quantities of cells are needed. 
Also, the assay is dependent on the correct timing of the crosslinking since protein-
DNA interactions are dynamic. As a negative control, we have used an IgG antibody.  
 
3.13 IMMUNOSTAINING, MICROSCOPY AND IMAGE ANALYSIS 
In paper III, we studied the localization and colocalization of PLIN1 and HSL. To this 
end, we performed sequential double immunocytochemical stainings with different 
secondary fluorescing antibodies. We compared the protein localization around the 
rim of the lipid droplet of both proteins in cells that had been treated with the LXR 
agonist GW3965 to vehicle-treated cells. We studied this using at least three z-stacks 
after deconvolution from three different lipid droplets in three different cells per 
patient. We calculated the relative amount of PLIN1 and also the ratio of PLIN1 over 
HSL and compared the results from the vehicle-treated and LXR-agonist treated cells.  
 
3.14 STATISTICS 
For statistical analyses in general, it is often recommended that the number of subjects 
and objects should not be lower than 30 per group in order to ensure that the data will 
be normally distributed. This is however often not possible when it comes to 
experimental research, due to technical limitations. It would take very long time; the 
material might be precious and the reagents very expensive. In our studies, primary 
cells from 3-6 individuals are used and non-parametric tests are applied. 
 
With regards to the clinical data in paper I, a power calculation based on the previously 
known distribution of CIDEA mRNA expression was performed before subjects were 
recruited. The patients were recruited in a ratio of 1:2:3 with regards to control patients, 
weight stable cancer patients and cancer cachexia patients. This ratio suggested, based 
on the assumption of a 10% experimental failure rate and mean and SD of CIDEA 
mRNA, that 1:16:24 patients had to be recruited to detect a 2-fold difference between 
cachexia and the two other groups at <0.05 (using ANOVA) with 80% power using 
sample power (SPSS, Inc). In the analysis of data, results were compared using 
ANOVA and appropriate post hoc test, chi-squared test, unpaired or paired t-test and 
linear/multiple regression analysis. When comparing SGA and tumor scores, Kruskal-
Wallis and Mann-Whitney tests were used.  
 
For the experimental part of paper I and in papers II and III, the statistical analysis was 
performed using Student’s t-test or Mann-Whitney test, using standard statistical 
software.   
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4 RESULTS AND DISCUSSION 
 
In this section, I will summarize and comment the results from the individual papers, 
focusing on the aims previously outlined in section 2. In section 5, I will summarize 
the results from the different papers and provide some future perspectives.  
 
4.1 PAPER I 
The aim of paper I was to study a novel concept in the role of fat loss in cancer 
cachexia, namely the function of CIDEA. Also, a number of metabolism-related 
clinical parameters were assessed and compared between the three study groups: 
cancer cachexia, weight-stable cancer patients and noncancer patients.  
 
The clinical data is shown in table 1 in paper I. Even though the subjects with cancer 
cachexia had a lower BMI, body fat percent and total amount of body fat compared to 
the other groups, lean body mass was similar in both cancer groups. The cancer 
cachexia group reported a more pronounced weight loss, and had a higher subjective 
global assessment score (SGA). SGA is a nutritional assessment method where a high 
score is indicative of malnourishment. The patients with cancer cachexia also had 
lower levels of markers of anabolism, such as plasma TG and serum albumin, 
compared to the other two groups. Lipid mobilization, measured as plasma FFA or 
plasma glycerol concentrations, corrected for total body fat, was increased in the 
cancer cachexia group. Finally, the RQ was significantly decreased in the cancer 
cachexia group, compared to the noncancer and weight-stable cancer group, 
indicating that this group had a high level of lipid oxidation, rather than carbohydrate 
oxidation. 
 
CIDEA is an interesting gene since it is almost exclusively expressed in white 
adipocytes in humans and brown adipocytes in mice. It has also been shown to be up-
regulated in human WAT after weight loss [82]. Since earlier studies indicated that 
CIDEA might be important for adipocyte metabolism, we decided to investigate if it 
could play a role in cancer cachexia. We measured the mRNA levels of CIDEA in 
WAT from patients suffering from cancer cachexia and could show that the 
expression of CIDEA was higher in this group, compared to the weight stable cancer 
patients and the noncancer patients. BMI and adipose mass correlated strongly and 
negatively with CIDEA levels. There was no correlation between CIDEA levels and 
lean body mass, indicating that CIDEA expression in adipocytes might be important 
for total fat mass.  It is difficult to elucidate whether the strong correlation between 
reported weight loss and CIDEA mRNA expression in WAT is due to a loss of body 
weight per se or to the catabolic state of the cancer cachexia patients.  
 
It has previously been shown that changes in the metabolism can influence the FFA 
oxidation in WAT. Patients with cancer cachexia have an increased lipolysis and an 
elevated FFA mobilization. In this study, it was evident that the cancer cachectic 
patients had a lower RQ compared to the other groups, and that CIDEA expression in 
all subjects was strongly correlated with RQ. A low RQ, indicating a high FFA-
oxidation, was associated with high CIDEA mRNA levels, and as much as 25% of 
the variation in RQ could be explained by CIDEA, according to calculations of 
adjusted r2. Also, reported weight loss was negatively correlated with RQ. 
Furthermore, multiple regression analysis showed that only CIDEA was a significant 
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regressor for RQ when either BMI or body fat was used together with CIDEA as an 
independent regressor and RQ as the dependent variable. 
 
Next, we wanted to elucidate the potential impact of high CIDEA levels on 
metabolism in white adipocytes. Human CIDEA was over-expressed in two different 
cell systems: murine 3T3-L1 and human preadipocytes, differentiated in vitro. In both 
these cell systems, CIDEA is expressed at very low levels. Cells with increased levels 
of CIDEA showed a higher fatty acid oxidation, compared to control. This is in line 
with the clinical data showing that high mRNA levels of CIDEA correlates with low 
RQ, indicating a high fatty acid oxidation. Also in line with these findings, over-
expression of CIDEA decreased glucose oxidation in 3T3-L1 cells. Since CIDEA 
belongs to a proapoptotic family, it is important to note that CIDEA did not induce 
necrosis or apoptosis when over-expressed in this setting. 
 
The next step in mapping the pathway or pathways behind CIDEAs effects on 
substrate oxidation was to compare mRNA levels of important regulatory genes in the 
oxidation cascade in cells with over expressed CIDEA against control. However, the 
increased levels of CIDEA did not affect known regulators such as Cpt-I and 
HADHA. In contrast, levels of PDK1 and PDK4 were increased in cells with high 
levels of CIDEA, compared to control. In the clinical material, there was a correlation 
between expression of PDK1/PDK4 and CIDEA mRNA levels. The correlation was 
strong, as much as 46% of the variation in PDK1 and 58% of the variation in PDK4 
could be explained by variation of CIDEA.  
 
As described in the introduction, the PDKs regulate the activity of the PDC – and 
thereby the cellular substrate oxidation. The PDKs inhibits the PDC by 
phosphorylation, which results in a higher degree of lipid oxidation and a lower 
glucose oxidation. Therefore, we investigated the phosphorylation status of the PDC. 
In lysates from cells with over-expressed CIDEA the phosphorylation of PDC was 
stronger compared to control. This is indicative of a decreased activity of the complex 
and thereby and a shift in the substrate oxidation from glucose to lipids. The up-
regulation of FFA oxidation by CIDEA might be a protective mechanism for 
handling the increased levels of FFA due to the augmented lipolysis connected to the 
cancer cachexia. It should be mentioned that CIDEA has previously been shown to 
inhibit lipolysis. However, in the case of cancer cachexia the stimulated lipolysis is 
increased, most probably due to enhanced expression and function of HSL [5], 
overriding the inhibitory effects on basal lipolysis caused by high CIDEA.  
 
In this paper, we suggest that CIDEA is involved in the altered lipid metabolism 
associated with cancer cachexia. In our cohort, the cancer cachexia patients show 
clear signs of malnutrition, however the lean body mass is unaltered. Furthermore, 
they display an increased lipolysis, FA mobilization and lipid oxidation, compared to 
the noncancer and the weight-stable group. We propose that expression of CIDEA is 
increased, leading to up-regulation of PDK1 and PDK4. The PDKs phosphorylate the 
PDC, causing a decreased activity and thereby inducing the use FFAs instead of 
glucose for acetyl-CoA oxidation via the TCA cycle. It is difficult to speculate about 
the mechanism behind CIDEA up-regulation in cancer cachexia. There have been 
discussions regarding the possible presence of cachexia factors. The hypothesis 
suggests that so far unknown factor, or several factors, could up-regulate the 
expression of HSL, and thereby increase lipolysis in adipocytes. ZAG has been 
proposed as a potential cachexia factor since it has been shown to up-regulate 
lipolysis [140, 141]. A recent paper suggests that ZAG acts locally in the adipose 
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tissue [79]. This paper also suggests that ZAG might be a catabolism factor and not 
necessarily a cancer cachexia aspect, since ZAG levels in the AT and plasma glycerol 
and free fatty acids are enhanced in subjects given a very low calorie diet (VLCD). In 
a different study, CIDEA levels were increased in the AT of patients on VLCD [89]. 
Taken together, this suggests a possible co-regulation of ZAG and CIDEA. Both 
proteins seem to be up-regulated by a catabolic state and it is not possible to say if 
one regulates the other or if an unknown factor regulates both proteins 
simultaneously. It is difficult to speculate about how CIDEA could regulate the 
expression levels of PDK1 and 4 since CIDEAs role in gene regulation in general is 
unknown. However, it could be of great interest to further study the relationship of 
CIDEA and ZAG to acquire additional insight into the regulation of adipocyte 
metabolism in cancer cachexia. Since cancer cachexia in many ways is the opposite 
of obesity, gaining more knowledge about the pathways involved is of interest also 
with regards to obesity and type 2 diabetes, besides the importance in the cancer field. 
  
4.2 PAPER II 
The aim of paper II was to study the effect of LXR activation on substrate oxidation in 
human adipocytes and try to elucidate the underlying mechanism. As previously 
described, the oxidation of FFAs might function as a protective mechanism when the 
circulating levels of FFAs rise. High circulating levels of FFA are well known to 
promote insulin resistance and, in turn, type 2 diabetes. Even though skeletal muscle is 
the major site for lipid oxidation in humans, the adipocytes contribute to the total 
energy expenditure [39], and the capacity of human WAT to oxidize FFAs may change 
when the oxidative machinery is altered [41].   
 
When we stimulated in vitro differentiated human adipocytes with the LXR agonist 
GW3965 β-oxidation was up-regulated, both in a time- and concentration-dependent 
manner. To try to find a pathway for the up-regulation of lipid oxidation, we measured 
the mRNA levels of several important β-oxidation genes in cells treated with GW3965 
or vehicle. Similar to the results from paper I, we could not see any effect on known 
regulators such as Cpt-I and HADHA. Since LXR has previously been shown to up-
regulate levels of PDK4 in muscle cells, we measured the mRNA levels of PDK1 and 
PDK4. We could show that stimulation with a specific LXR agonist increased the 
levels of PDK4 in human adipocytes, on mRNA and also on protein level.  However, 
PDK1 was not affected. We then investigated the effect of LXR on the phosphorylation 
of the PDC. Since PDK4 can phosphorylate, and thereby inactivate, PDC and thus turn 
the cell towards favoring lipids over glucose as substrate for the TCA cycle, this could 
be how LXR regulates lipid oxidation. When LXR is activated in human adipocytes, 
the phosphorylation of PDC is increased and the activity, measured by a novel dipstick 
assay, is decreased. As expected, glucose oxidation is also decreased.  
 
In order to see if the effect of LXR on substrate oxidation is PDK4-specific, we 
performed knockdown studies. We successfully silenced PDK4 in human adipocytes 
using siRNA and subsequently measured the effect of GW3965-stimulation on glucose 
oxidation, lipid oxidation and PDC-phosphorylation. We also measured a set of genes 
not directly related to β-oxidation, in order to exclude possible non-target effects in our 
system. We also measured PDK1, which was not affected by the PDK4 knockdown. 
The knockdown of PDK4 in human adipocytes abolished the effect of GW3965 on 
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glucose oxidation and diminished the PDC phosphorylation upon treatment with the 
LXR agonist. The knockdown of PDK4 did not affect lipid oxidation in the adipocytes, 
indicating that other mechanisms might be important for the LXR-activated up-
regulation of β-oxidation. The elevation of FFAs themselves might cause an up-
regulation of lipid oxidation, since it has previously been shown in muscle that reduced 
FFA availability can increase PDH activity through differences in the NADH/NAD+ 
ratio [142].   
 
We also performed knockdown studies of LXR to investigate whether the effect of the 
LXR agonist truly were mediated by LXR. We knocked down both isoforms 
simultaneously and measured lipid oxidation. In cells lacking LXR no GW3965-
mediated up-regulation of β-oxidation was present, indicating that the effects of the 
LXR agonist are specific for LXR activation.  
 
In the last section of paper II we looked into the effect of LXR on substrate oxidation in 
murine 3T3-L1 adipocytes. The results were highly similar to the data obtained in 
human adipocytes, and described above. Lipid oxidation was up-regulated, glucose 
oxidation attenuated, mRNA levels of PDK4 increased and the PDC showed an 
increased degree of phosphorylation. This strengthens the results from the human 
adipocytes and suggests no species specificity in this process, at least concerning 
humans and mice. 
 
In this paper, we demonstrate that LXR activation can increase lipid oxidation and 
decrease glucose oxidation. This is, at least regarding glucose oxidation, due to an 
increase in PDK4 and a concomitant phosphorylation of the PDC. We show that the 
LXR-agonist mediated effects are true LXR effects since they are abrogated by LXR 
silencing. Up-regulation of PDK4 and decrease in PDC activity in muscle have been 
associated with development of diabetes [143]. The effect in adipocytes, however, 
might be different since it might decrease FFA output from adipocytes, diminishing 
deleterious effects of increased circulating levels of FFA connected to a increased 
lipolysis. The possible effect of LXR activation in WAT in general will be discussed 
more in detail in paragraph 5. 
 
4.3 PAPER III 
In paper III, we have studied the role of LXR activation on basal human adipocyte 
lipolysis and described a potential mechanism for LXR action in this pathway. As 
described above, lipolysis is one of the central events in adipocyte metabolism. The 
process of lipolysis is tightly regulated in order to ensure a good supply of energy to 
other tissues in the form of lipids when needed. At the same time, it is important to 
keep the rate of lipolysis at an appropriate level so that energy stores will not be wasted 
at incorrect times. This balance is disrupted in obesity, where the basal lipolysis is 
increased, partly due to increased adipocyte size. There is a clear connection between 
augmented levels of circulating FFAs and insulin resistance, and thereby type 2 
diabetes.  
 
When we stimulated in vitro differentiated human adipocytes and murine 3T3-L1 cells 
with the LXR agonist GW3965, the release of glycerol was increased. Since the end 
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products of lipolysis are one molecule of glycerol and three FFAs, and glycerol cannot 
be utilized within the adipocytes, levels of glycerol are an appropriate measurement of 
lipolysis. We could also show that the LXR-effect of lipolysis is independent of re-
esterification, since the relative up-regulation of lipolysis by LXR activation was 
similar in cells treated with an inhibitor of re-esterification and control cells. Next, we 
wanted to elucidate the pathway behind the increased lipolysis. We performed 
microarray analysis on RNA from human adipocytes, differentiated in vitro and treated 
with GW3965 for 24h. We analyzed cells from five different subjects; details on the 
statistical analysis have been described in section 3.10. The results from the microarray 
showed that around 6% of all genes represented on the microarray ChIP was affected 
by the LXR activation and among the genes involved in lipolysis, 25% of the genes 
were affected. These genes are listed in table 1 in paper III. 
 
To elucidate the pathway behind the LXR-related up-regulation of lipolysis and 
confirm the results from the microarray, we performed qRT-PCR measurements on 
samples from adipocytes treated with GW3965 or vehicle for 6, 12 or 24 hours. We 
could confirm several genes indicated as potential candidates from the microarray 
analysis and also showed that the effect was rather quick, the mRNA levels of several 
genes were significantly altered after only 6 or 12 hours of GW3965-stimulation. We 
saw a dramatic reduction of mRNA levels of HSL, PLIN1, CGI-58 and CIDEC upon 
treatment with GW3965. However, the expression of PPARγ was not affected by the 
LXR activation. Of these, we could confirm HSL, PLIN1 and CIDEC on protein level 
and decided to continue with HSL and PLIN1, two major lipolysis-regulators, 
potentially regulated by LXR. We studied the localization of both these proteins 
simultaneously in cells treated with GW3965 or vehicle and could detect a difference in 
the localization pattern around the lipid droplet. The presence of PLIN1 around the 
lipid droplet was lower in cells with activated LXR, compared to control. Also, the 
ratio of HSL/PLIN1 was higher. A higher level of HSL combined with a lower amount 
of PLIN1 on the rim of the lipid droplet could increase lipolysis.  Next, we studied if 
HSL phosphorylation and activity is affected by the LXR activation. 
 
When HSL is phosphorylated by PKA, lipolysis is affected. We used Western Blot to 
investigate the phosphorylation status of some HSL-phosphorylation sites known to 
affect lipase activity. We could conclude that LXR does not affect HSL 
phosphorylation, at least not on the sites investigated here, since the phosphorylated 
forms of HSL were down-regulated to the same extent as total HSL protein. Using the 
specific HSL inhibitor BAY we could show that LXR’s effect on lipolysis is dependent 
on functional HSL, since the up-regulation of glycerol release is abolished when HSL is 
inhibited in human in vitro differentiated adipocytes.   
 
Since the data above indicates that HSL activity is most probably unaffected by LXR 
activation and the relative down-regulation of PLIN1 protein compared to HSL is more 
dramatic, we hypothesized that PLIN1 might be the main factor in LXR-mediated 
lipolysis. We knocked down PLIN1 in human adipocytes using RNAi and measured 
the levels of glycerol release. As expected, a diminished expression of PLIN1 caused 
an increased basal lipolysis. However, we could show that the LXR-effect was 
abolished in cells lacking PLIN1. This indicates that the down regulation of PLIN1 
might be the main mechanism for LXR-mediated up regulation of lipolysis. 
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Since LXR acts as a transcription factor, we hypothesized that LXR could bind to the 
promoter of PLIN1. In order to investigate this, we performed ChIP assays. We applied 
a bioinformatical search using the MatInspector software to search for potential LXREs 
in the PLIN1 promoter, 3.5 kbp upstream of the transcription start site. However, we 
could not detect any LXREs using the MatInspector software. Instead, we designed 
nine primer pairs. The amplified sequences overlap potential PPARγ response elements 
(PPREs), RXR sites or represent the most proximal regions of the promoter. We 
compared the enrichment of LXR on the different promoter fragments in material from 
adipocytes treated with GW3965 or vehicle and could show that LXR activation lead to 
a higher degree of enrichment of LXR binding on the most proximal parts of the PLIN1 
promoter. We also performed ChIP using an antibody against polymerase II (Pol II). 
The results indicate that there is less binding of Pol II to the most proximal parts of the 
PLIN1 promoter, in line with the diminished transcription of PLIN1 determined by 
qRT-PCR.  
 
We also wanted to study if LXR could bind directly to the promoter of HSL, using a 
similar approach. We could identify two weak LXREs, represented in primer pair 1 and 
2. However, we could not detect LXR binding to these sites. Instead, we could show 
enrichment of LXR to the most proximal parts of the HSL promoter, were the 
MatInspector software had detected several potential RXR sites. Also, the recruitment 
of Pol II to the HSL promoter was decreased in cells treated with GW3965, compared 
to control. This is similar to the results seen with PLIN1 and is in line with the 
decreased mRNA expression. LXR binding to the promoter of the well-established 
LXR gene ABCG1 was also enriched upon LXR activation. Furthermore, we show that 
LXR’s heterodimerization partner, RXR, is also recruited to the LXR binding regions 
of PLIN1 and HSL upon LXR stimulation in human adipocytes. It should be noted that 
the relative enrichment of LXR to PLIN1 was stronger than the enrichment of LXR to 
HSL upon LXR activation.  
 
We show that LXR binds to the promoters of both PLIN1 and HSL and that this 
binding leads to a negative gene regulation, supported by the Pol II data and mRNA 
and protein measurements. In general, LXREs have mostly been associated with 
positive gene regulation; however there are some reports indicating that LXR can 
suppress gene expression via interactions with cofactors and other transcription factors 
[96, 144]. We do not know if LXR binds directly to the promoters and/or if a cofactor 
is involved, however the kinetic mRNA data and ChIP results indicates that LXR 
regulates gene expression of HSL and PLIN1 through direct recruitment to the 
respective promoters of the genes. 
 
Both LXRα and LXRβ are expressed in adipocytes. To elucidate which isoform is 
responsible for the up-regulation of lipolysis in human adipocytes, we performed 
isoform-specific knockdowns using siRNA and measured expression of PLIN1 and 
glycerol release. We could show that although cells lacking LXRβ show a similar 
PLIN1-expression upon GW3965-stimulation, the down-regulatory effect of LXR 
activation is much weaker in cells lacking LXRα, but not in cells with diminished 
expression of LXRβ. This indicates that LXRα is the main isoform mediating the 
effects of LXR activation on lipolysis in human primary adipocytes.  
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In this paper, we show that activation of LXRα increases basal lipolysis in human and 
murine adipocytes in culture. Microarray analysis indicated that 25% of lipolysis-
related genes are affected by stimulation with the LXR agonist GW3965 and of these, 
we suggest that the down-regulation of PLIN1 is the most important factor. We propose 
that LXR binds to the promoter of PLIN1 upon LXR activation, thereby repressing 
PLIN1 expression. The localization of PLIN1 and HSL around the lipid droplet is also 
affected by GW3965, and furthermore, knockdown of PLIN1 abolished LXR’s up-
regulatory effect on glycerol release in human adipocytes. Through isoform-specific 
knockdown studies, we show that LXRα is the major isoform in LXR-related up-
regulation of lipolysis. 
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5 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
  
5.1  PAPER I: We show that CIDEA is involved in lipid oxidation in adipose 
tissue and the loss of fat mass associated with cancer cachexia. The 
ability of CIDEA to inactivate PDC, thereby switching the substrate 
oxidation in human adipocytes from glucose to lipids contributes to this 
process. 
5.2  PAPER II: We propose that LXR is an important regulator for substrate 
oxidation in both human and murine adipocytes. LXR activation 
inactivates the PDC, resulting in an increased lipid oxidation and 
decreased glucose oxidation. 
5.3   PAPER III: We suggest a new role for LXRα in the regulation of basal 
lipolysis in human and murine adipocytes. Ligand-mediated activation of 
LXR increases lipolysis, at least in part through binding to the promoter 
of PLIN1 and down-regulation of PLIN1 expression. 
 
There is still some controversy on the general role of CIDEA in adipocytes and also 
regarding the localization of CIDEA in human adipocytes. It could be appealing to 
study the cellular localization of CIDEA further, and also investigate whether post-
translational modifications might affect the localization, and thereby function, of the 
protein. Further studies of CIDEA are hampered by the lack of a known activator of the 
protein, which would be very helpful if one postulates that CIDEA can affect 
transcription of for example PDK1 and PDK4. 
 
The role of CIDEA in adipocyte metabolism in general and also in cancer cachexia 
needs be evaluated further. There might be a co-regulation of ZAG and CIDEA with 
effects on catabolism and/or cancer cachexia in human adipose tissue. Furthermore, it 
could be interesting to investigate the mechanism behind the down-regulation of 
CIDEA in obesity and the normalization of CIDEA expression upon weight loss.  
 
In paper II and III, the role of LXR in human adipocytes has been investigated. As 
described in the introduction, the role of LXR in adipocyte metabolism is puzzling due 
to controversial data from multiple laboratories. We suggest that LXR activation can 
increase both lipolysis and β-oxidation. This is in line with previous mouse model 
studies, where LXR agonist administration to mice resulted in smaller adipocytes and 
higher levels of glycerol in circulation, indicating that both breakdown and utilization 
of lipids is stimulated by LXR activation. These two processes might be coupled since 
an up-regulation of β-oxidation within the adipocyte could serve as a protective 
mechanism against the deleterious effects of increased FFA in circulation. If the 
adipocytes can metabolize a larger amount of the FFA, this could decrease the negative 
effects of circulating FFAs in other tissues, such as skeletal muscle and liver. Also, 
since WAT inflammation is coupled to increased circulating FFAs, an up-regulation of 
β-oxidation in adipocytes might also be important in the sense of adipocyte 
inflammation. LXRs role in adipocyte lipogenesis is debated, as described in the 
introduction. In the studies presented in this thesis, we have not showed measurements 
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of lipogenesis. However, since LXR is shown to increase both lipolysis and β-
oxidation, it seems unlikely that LXR activation would also increase lipogenesis in 
human adipocytes. The concept of manipulating white adipocytes to be more like 
brown adipocytes, adaptive thermogenesis, has been debated in the last few years. An 
increased fatty acid oxidation could be of great interest in this model, since the aim is to 
create a metabolic shift in white adipocytes from fat storage to lipid utilization. If the 
fatty acid oxidation could be increased by pharmacological means in the adipocyte 
itself, the burden of the FFA produced by lipolysis on other organs could be eased. 
 
We show that both LXR and RXR are recruited to two important genes in adipocytes, 
HSL and PLIN1, thereby repressing gene expression. This is an unusual finding in 
LXR biology, since LXREs have mostly been implicated in positive gene regulation. 
Also, we could not identify any LXREs in the regions of the promoters to which LXR 
and RXR are recruited. This might indicate indirect binding of LXR to the promoters of 
PLIN1 and HSL, or the presence of unknown LXREs, perhaps more strongly related to 
negative regulation of transcriptions. However, there are potential binding sites for 
nuclear factor kappa-B (NF-κB) in the regions where LXR is enriched on the promoters 
of both HSL and PLIN1. NF-κB has previously been shown to play a role in regulation 
of lipolysis in human adipocytes [145], and LXR can interfere with NF-κB signalling 
in macrophages [146]. Further studies on the potential role of the NF-κB site in the 
PLIN1 promoter will be of great interest in the future. 
 
As mentioned in the introduction, NRs have been regarded as promising targets for 
development of new pharmaceutical treatment. LXR was considered a very attractive 
candidate since it promotes reverse cholesterol transport and limit inflammation in 
macrophages. However, administration of LXR agonist to mice induced lipogenesis in 
liver and raised triglyceride levels. The data presented in this thesis indicate that further 
research on this is needed, and that isoform- and tissue specific agonists would be of 
great interest in this aspect. Previous reports have indicated that LXRα might be the 
main isoform regulating adipocyte metabolism [108, 114, 126] and in a previous study 
from our group, expression levels of LXRα was higher in WAT from obese women, 
compared to lean [98]. On this note, our data in paper III indicates that up-regulation of 
LXRα could have deleterious effects by increasing lipolysis, a process strongly linked 
to the development of insulin resistance and type 2 diabetes. It might be more attractive 
to up-regulate LXRβ, if the positive effects of LXR up-regulation on fatty acid 
oxidation could be maintained, without the deleterious effects on lipolysis. It should be 
noted, however, that we have not investigated isoform regulation in the aspect of 
substrate oxidation, and that mice lacking LXRβ show a different adipocyte phenotype, 
compared to wild type mice [111]. The generation of isoform- and tissue-specific 
knockout mice could be of great interest in this concept, since it would open to 
possibilities of investigating the role of each isoform in the adipose tissue specifically. 
As LXRβ is ubiquitously expressed, the effects seen in complete knockout mice might 
also be related to LXRs role in other tissues. 
 
Recently, a genome-wide profiling analysis of LXR, RXR and PPARα in mouse liver 
was published [147]. In this paper, the authors have performed ChIP sequencing of 
these three NRs and compared the data sets. This approach would be very interesting to 
apply in our human adipocyte system for identification of target genes regulated by 
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LXR. Furthermore, given the differential role for LXR isoforms, performing this 
analysis with isoform-specific LXR agonists or human cells lacking one of the isoforms 
would greatly add to our understanding. 
 
It has been proposed that LXRs are constitutively activated in adipocytes since these 
cells contain large deposits of cholesterols – a potential source of natural ligands. 
However, others, and we, have shown that LXRs can be activated to a high degree both 
in vivo and in vitro by endogenous and exogenous treatments. We have used the 
artificial LXR agonist GW3965 in our studies. Another alternative would have been 
TO91317, a readily used agonist. However, this agent is not specific for LXR since it 
also activates two other nuclear receptors, the farnesoid x receptor (FXR) and the 
pregnane x receptor (PXR) [148, 149]. On the other hand, we have used TO91317 as a 
parallel treatment in our systems and have seen similar results. Also, according to our 
own, unpublished results, neither FXR nor PXR is expressed in human adipocytes. It 
would be very interesting to find the endogenous activator/activators of LXR in 
adipocytes, and to study if this potential substance/substances activates both isoforms 
symmetrically and at the same time, or if there is a dynamic regulation of the LXR 
isoforms, as seen in adipocyte differentiation, where LXRα is up-regulated while 
LXRβ is unchanged. 
 
There are three splice variants of LXRα [99], as mentioned in the introduction. 
Preliminary results from our laboratory indicate that one of the less abundant splice 
variants might be present in human fat cells. It is not known, to date, what the 
respective roles of these splice variants are. This would be attractive to explores, since 
the role of LXR in adipocytes appears to diverge from the role of LXR in other cell 
types 
 
In a recent paper from our group, CIDEA was shown to interact with LXR [93]. 
CIDEA binds LXR both in vitro and ex vivo and can repress LXR-regulated reporter 
constructs in 3T3-L1 cells. These findings might seem confusing since both LXR and 
CIDEA can enhance substrate oxidation by up-regulation of PDK4 (paper I and II) and 
also, both proteins have been shown to up-regulate lipolysis (paper III and [82]). 
However, the physiological importance of the interaction of CIDEA is not known, and 
since LXR might affect several aspects of adipocyte metabolism, additional studies are 
required to see which aspects of LXR function that might be affected by a potential 
crosstalk between CIDEA and LXR. It would be very interesting to investigate the 
interaction between CIDEA and LXR further, and include studies in human cells.  
 
The cell studies in this thesis have been performed in in vitro differentiated human 
adipocytes and 3T3-L1 cells. As described in section 3.2, these systems have their 
drawbacks. It could therefore be an attractive approach to try to confirm the data 
obtained in this thesis in a different cell system, namely mature human adipocytes.  
This approach might be more physiological, but is also technically challenging. The 
mature adipocytes, isolated fresh from human WAT, are fragile and difficult to keep in 
culture for long periods of time. We have nonetheless recently adapted a technique 
where we can keep the cells alive in culture for up to 72 hours. These cells respond well 
to lipolysis stimulation and stimulation with an LXR agonist. According to unpublished 
data, the mRNA expression of both CIDEA and LXR might be different in these cells. 
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Also, the effects of LXR activation might differ in these cells, compared to in vitro 
differentiated adipocytes.  
 
In conclusion, we have shown that LXR and CIDEA can regulate important functions 
of human adipocyte metabolism. This is of importance for states with disturbed AT 
function, such as obesity and cancer cachexia. The findings presented in this thesis 
open the field for many more potential research projects, including elucidating the 
possible co-regulation of CIDEA and ZAG, further in-depth analysis of LXRs role in 
adipocytes using different techniques such as ChIP-sequencing and isoform- and/or 
tissue-specific knockout mice and further examinations of protein-protein interactions 
between LXR and CIDEA. It would also be of interest to examine the role of LXR and 
CIDEA in human mature adipocytes. Since states affecting the AT, foremost obesity 
but also cachexia, are major health problems it is of great substance to understand 
adipocyte biology and how it is affected by states of health and disease.  
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